Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
तुलना करने के लिए मीट्रिक्स | GILD34 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGILD34पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 913.7x | −1.5x | −0.6x | |
PEG अनुपात | −9.32 | −0.01 | 0.00 | |
क़ीमत/बुक | 6.2x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.1x | 5.8x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 561.8% | 45.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 25.0% | 7.7% | अनलॉक करें |